The Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) drugs in development market research report provides comprehensive information on the therapeutics under development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) and features dormant and discontinued products.
GlobalData tracks six drugs in development for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) by six companies/universities/institutes. The top development phase for Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) is phase i with two drugs in that stage. The Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline has five drugs in development by companies and one by universities/ institutes. Some of the companies in the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline products market are: ProMIS Neurosciences, Neural Stem Cell Institute and Cortice Biosciences.
The key targets in the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline products market include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT), Rho Kinase (Rho Associated Coiled Coil Forming Protein Kinase or ROCK or EC 2.7.11.1), and TAR DNA Binding Protein 43 (TDP43 or TARDBP).
The key mechanisms of action in the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline product include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT) Inhibitor with three drugs in Preclinical. The Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline products include two routes of administration with the top ROA being Oral and three key molecule types in the Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) pipeline products market including Small Molecule, and Antibody.
Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration) overview
Corticobasal degeneration (CBD) or corticobasal syndrome (CBS) is a rare neurological disorder that causes brain cells to die or become damaged. CBD is a form of frontotemporal degeneration, a dementia that involves the loss of cognitive functions that can gradually lead to worsening of movement, speech, memory, and swallowing. Symptoms include a clumsy or useless hand, muscle stiffness, shaking hands (tremors) and muscle spasms (dystonia), and “alien” limb sensation. A brain scan such as MRI may be used to diagnose CBD. There is no cure for CBD; physical and occupational therapy and speech therapy are used to relieve the symptoms.
For a complete picture of Corticobasal Degeneration (CBD/CBGD/Cortical Basal Ganglionic Degeneration)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
